July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Drug Screening and Hit Identification for Retinitis Pigmentosa with Zebrafish
Author Affiliations & Notes
  • Logan Ganzen
    Purdue University Interdisciplinary Life Sciences Program, Purdue University, West Lafayette, Indiana, United States
    Purdue Institute for Integrative Neuroscience, Purdue University, West Lafayette, Indiana, United States
  • Chi Pui Pang
    Department of Ophthalmology and Visual Sciences, Chinese University of Hong Kong, Kowloon, Hong Kong
  • Mingzhi Zhang
    Joint Shantou Eye Center, hantou University & the Chinese University of Hong Kong, Shantou, China
  • Motokazu Tsujikawa
    Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan
  • Yuk Fai Leung
    Department of Biological Sciences, Purdue University, West Lafayette, Indiana, United States
    Purdue Institute for Drug Discovery, Purdue University, West Lafayette, Indiana, United States
  • Footnotes
    Commercial Relationships   Logan Ganzen, None; Chi Pui Pang, None; Mingzhi Zhang, None; Motokazu Tsujikawa, None; Yuk Fai Leung, None
  • Footnotes
    Support  NIH Grant KL2TR001106
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5335. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Logan Ganzen, Chi Pui Pang, Mingzhi Zhang, Motokazu Tsujikawa, Yuk Fai Leung; Drug Screening and Hit Identification for Retinitis Pigmentosa with Zebrafish. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5335.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Retinitis Pigmentosa (RP) is an incurable disease which affects approximately 1 in 4000 individuals globally. Since there are no effective treatment options for RP, the goal of this project is to identify novel drug treatments that can prevent or slow the disease progression. To this end, we optimized a behavioral assay, visual-motor-response (VMR) assay, to investigate rod function (Ganzen et al., ARVO 2017) (Ganzen et al., IJMS 2017). This was done utilizing a transgenic zebrafish RP model expressing human rhodopsin with the Q344X mutation. In this study, we used this model to perform a proof-of-concept screen for drugs which may improve the vision of the larvae.

Methods : To screen for beneficial drugs, the SCREEN-WELL® REDOX library was chosen for screening. This library was selected to identify a compound that may alleviate any excessive oxidative stress in the diseased retina. The Q344X zebrafish line suffers from significant rod degeneration by 7 days post-fertilization (dpf) and displayed deficits in VMR under scotopic conditions (Ganzen et al., ARVO 2017). The Q344X larvae were drug treated beginning at 5 dpf at 10 μM. Compounds that were toxic at this concentration were retested at 1 μM. The 5 dpf stage was chosen as most of the rods are intact, and these concentrations were chosen to optimize the drug effect based on similar studies. Hits were identified by assays that provided a robust and reproducible enhancement in the Q344X VMR. The retinae of any drug hits were dissected from larvae crossed with a rod EGFP reporter line and whole-mounted to analyze rod survival via fluorescence. To determine if drug effects were exerted through the retina, eyeless chokh mutant zebrafish were exposed to the drug and tested with the same assay.

Results : Of the 84 compounds tested, we identified 1 drug that ameliorated the VMR of the Q344X scotopic VMR. Eyeless chokh mutant zebrafish larvae did not exhibit the same VMR when treated with the same drug. Histological analysis suggested increased rod survival in the drug-treated retina of Q344X mutants.

Conclusions : These results indicate that the vision of the Q344X zebrafish was improved via this beneficial drug treatment. Since eyeless chokh larvae did not respond to the same treatment, the drug likely mediated its positive effects through the Q344X retina, likely by improving of rod survival. Together, our results have identified a beneficial drug that may treat RP.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.